ReviewCurrent cancer drug targets2026
Mechanism of Bispecific Antibodies and Clinical Research Advances in Lung Cancer.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung cancer is an aggressive malignancy and one of the leading causes of cancerrelated mortality worldwide. Compared with traditional treatments, the development of precision treatment programs, such as targeted therapy and immunotherapy, has progressively transformed non-small cell lung cancer (NSCLC) with driver mutations, becoming a clinically controllable chronic disease. Among the treatments for lung cancer, monospecific antibodies gradually show effectiveness but also expose their susceptibility to drug resistance, off-target effects, and other limitations. Therefore, bispecific antibodies have been developed, which have two different antigen-binding sites so that they can bind two distinct antigens or two distinct epitopes of the same antigen with adjustable specificity and do not easily produce drug resistance. This article reviews the design strategies and mechanism of bispecific antibodies, summarizes the latest progress in clinical trials involving bispecific antibodies for lung cancer, and analyzes the current challenges and future directions in this area of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.